Advocacy intelligence hub — real-time data for patient organizations
Northwestern University — EARLY_PHASE1
University of Auckland, New Zealand
Sohag University — NA
The University of Texas Health Science Center, Houston — NA
Kerecis Ltd. — PHASE4
University Hospital, Toulouse — PHASE2
Maastricht University Medical Center — NA
Maastricht University Medical Center — NA
Northwestern University — EARLY_PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Dermacure
(UREA 41%)Orphan drugstandardOncora Pharma, LLC
Urea 39.5% With 2% Salicylic Acid
(UREA, SALICYLIC ACID)Orphan drugstandardPureTek Corporation
Urea Cream 40 Percent
(UREA)Orphan drugstandardMethod Pharmaceuticals, LLC
William B. Rizzo, MD, DMD
University of Nebraska
📍 ORLANDO, FL
Tony Andrasfay
Therapeutics, Inc.
Adeline Vanderver, MD
Children's Hospital of Philadelphia
📍 Los Angeles, California
Emma Guttman-Yassky, MD, PhD
Mt. Sinai Hospital Department of Dermatology
Juliette Mazereeuw-hautier, MD
University Hospital of Toulouse
📍 Toulouse, Centre Hospitalier Universitaire de Toulouse
Amy Paller, MD, MD
Northwestern University Department of Dermatology
📍 CHICAGO, IL